Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Ibrance (Registered).

Trial Profile

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Ibrance (Registered).

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 May 2018

At a glance

  • Drugs Palbociclib (Primary)
  • Indications Adenocarcinoma; Breast cancer
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 16 May 2018 Planned End Date changed from 28 Apr 2023 to 30 Apr 2022.
    • 16 May 2018 Planned primary completion date changed from 28 Apr 2023 to 30 Apr 2022.
    • 04 Apr 2018 Planned End Date changed from 30 Apr 2022 to 28 Apr 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top